Claims for Patent: 8,088,567

Summary for Patent: 8,088,567

Title:	Human immortalised neural precursor cell line
Abstract:	The present invention relates to an immortalized human neural precursor cell line, NGC-407. The cell line has been established from human foetal tissue. The cell line has been immortalized using a retroviral vector containing the v-myc oncogene. The cell line is a neural progenitor cell line capable of differentiating into to astrocytes and neurons including dopaminergic neurons. NGC-407 cells are capable of migrating to glioblastoma tumours implanted into rat brains and form gap junctions with the tumour cells. NGC-407 cells expressing a suicide gene can be be used for delivering activated prodrugs in the form of activated nucleoside analogs to tumours.
Inventor(s):	Juliusson; Bengt (Ballerup, DK)
Assignee:	NsGene A/S (Ballerup, DK)
Application Number:	11/910,285
Patent Claims:	1. The isolated human NGC-407 cell line deposited under the Budapest Treaty with Deutsche Sammlung von Mkroorganismen and Zellkulturen, on 31 Mar., 2005, under accession number DSM ACC2718 or an isolated cell line obtainable therefrom. 2. The isolated cell line of claim 1, being a polyclonal cell line. 3. The isolated cell line of claim 1, being a monoclonal cell line. 4. The isolated cell line of claim 1, being transfected or transduced with an expression construct capable of directing the expression of a heterologous therapeutic gene. 5. The isolated cell line of claim 4, wherein the heterologous gene encodes a therapeutic polypeptide. 6. The isolated cell line of claim 4, wherein the heterologous gene comprises a suicide gene. 7. The isolated cell line of claim 6, wherein the suicide gene encodes a polypeptide selected from the group consisting of: a. a deoxyribonucleoside kinase having the amino acid sequence of any of SEQ ID No 1 to 17; b. a polypeptide comprising an amino acid sequence having at least 95% sequence identity to any of SEQ ID No 1, 4, 6, 7, or 17, wherein the amino acid sequence has deoxyribonucleoside kinase activity; and c. a polypeptide comprising an amino acid sequence having at least 90% sequence identity to any of SEQ ID No 2, 3, 5, 8, or one of 9-16, wherein the amino acid sequence has deoxyribonucleoside kinase activity. 8. The isolated cell line of claim 7, wherein the suicide gene encodes a polypeptide selected from the group consisting of: a. a deoxyribonucleoside kinase having the amino acid sequence of any of SEQ ID No 1 to 5; b. a polypeptide comprising an amino acid sequence having at least 95% sequence identity to SEQ ID No 1 or 4, wherein the amino acid sequence has deoxyribonucleoside kinase activity; and c. a polypeptide comprising an amino acid sequence having at least 90% sequence identity to any of SEQ ID No 2, 3, or 5, wherein the amino acid sequence has deoxyribonucleoside kinase activity. 9. The isolated cell line of claim 4, wherein the heterologous therapeutic gene encodes a neurotrophic factor. 10. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a neuronal survival factor. 11. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a nerve growth factor. 12. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a biologically active molecule that participates in the synthesis of a neurotransmitter substance. 13. The isolated cell line of claim 12, in which the neurotransmitter substance is acetylcholine, noradrenaline, adrenaline, 3,4-dihydroxyphenylalanine (L-DOPA), dopamine, octopamine, glutmate, aspartate, glycine, proline, .chi.-aminobutyric acid (GABA), tyrosine, taurine, alamine, cystathione, histamine, serotonine (5-hydroxytryptamine), substance P, Neuropeptid Y (NPY), Cholecystokinin, neurotensin, enkephalins, or somatostatin. 14. The isolated cell line of claim 2, in which the heterologous therapeutic gene is encoding a receptor. 15. The isolated cell line of claim 6, in which the suicide gene is a thymidine kinase (TK) gene. 16. The isolated cell line of claim 1, being capable of differentiating into astrocytes. 17. The cell line of claim 1, being capable of differentiating into neurons, such as dopaminergic neurons. 18. The cell line of claim 1, being capable of differentiating into glia. 19. The isolated cell line of claim 1, being capable of growing as an adherent culture. 20. The isolated cell line of claim 9, wherein the neurotrophic factor is a Nerve Growth Factor (NGF), an Insulin-like Growth Factor (IGF), a member of the Transforming Growth Factor (TGF) superfamily, Neurturin (NTN), Persephin (PSP); a Glial cell-line Derived Neurotrophic Factor (GDNF); Neublastin (NBN); a Ciliary Neurotrophic Factor (CNTF); a Brain Derived Neurotrophic Factor (BDNF); a Neurotrophin (NT), or a Tumor Necrosis Factor (TNF). 21. The cell line of claim 10, in which the neuronal survival factor is a Super Oxide Dismutase (SOD) or a Hedgehog. 22. The cell line of claim 11, in which the nerve growth factor is a Fibroblast Growth Factor (FGF), an Endothelial Growth Factor (EGF), an interferon, or an interleukin (IL). 23. The cell line of claim 12, in which the biologically active molecule that participates in the synthesis of a neurotransmitter substance is a choline acetyl transferase; a Tyrosine Hydroxylase (TH); a tyrosine decarboxylase; a thymidine kinase, a cytosine deamidase, a monoamine oxidase, a L-DOPA decarboxylase, a histidine decarboxylase, a glutamate decarboxylase, or an Ornithine Transcarbamylase (OTC). 24. The cell line of claim 14, in which the receptor binds acetylcholine, noradrenaline, adrenaline, 3,4-dihydroxyphenylalanine (L-DOPA), dopamine, octopamine, glutamate, aspartate, glycine, proline, .chi.-aminobutyric acid (GABA), tyrosine, taurine, alanine, cystathione, histamine, serotonine(5-hydroxytryptamine), substance P, Neuropeptid Y (NPY), Cholecystokinin, neurotensin, enkephalins, or somatostatin. 25. The cell line of claim 15, in which thymidine kinase (TK) gene is Herpes Simplex Virus thymidine kinase gene, the cytomegalovirus thymidine kinase gene, the varicella-zoster virus thymidine kinase gene the Gpt gene, or the cytosine deaminase gene. 26. The isolated cell line of claim 17, being capable of differentiating into dopaminergic neurons.

Details for Patent 8,088,567

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2025-04-01